Mark Genovese
Corporate Officer/Principal chez ELI LILLY AND COMPANY
Profil
Mark Genovese is currently the Senior Vice President-Immunology Development at Eli Lilly & Co. He previously worked as the Director at Kyverna Therapeutics, Inc. and as the Clinical Chief-Immunology & Rheumatology at Stanford University.
From 2020 to 2023, he served as the Senior Vice President-Inflammation Development at Gilead Sciences, Inc. Dr. Genovese completed his undergraduate degree at the University of Notre Dame and obtained his doctorate from The Johns Hopkins University School of Medicine.
Postes actifs de Mark Genovese
| Sociétés | Poste | Début |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 16/10/2023 |
Anciens postes connus de Mark Genovese
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/09/2023 |
| KYVERNA THERAPEUTICS, INC. | Director/Board Member | - |
| Stanford University | Corporate Officer/Principal | - |
Formation de Mark Genovese
| University of Notre Dame | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
